Scholarlink

Background <p>Septic arthritis (SA) is a rare but serious disease. There is no reliable marker for rapid diagnosis. Synofast® is a new device that analyses synovial fluid and can accurately rule out SA within 15&#xa0;minutes.</p> Objective <p>To evaluate the diagnostic performance of Synofast® in routine practice in patients with suspected SA and to assess its impact on patient care.</p> Method <p>This was a monocentric prospective study of patients with acute arthritis of possible septic origin. In addition to the usual blood and synovial bacteriological tests, a drop of synovial fluid was taken for the Synofast® test, which provides three SA risk probabilities: “low”, “possible” or “high”. The physician recorded the management he would have given before the test and the management he actually gave after the test, knowing the diagnostic performance reported in previous studies.</p> Results <p>Over one year, 43 patients were included, of whom eight had SA (18.6%). Sensitivity, negative predictive value (PV) and negative likelihood ratio (LR) were respectively of 75%, 93% and 0.32 when analysing for “high” and “possible” septic risk while specificity, positive PV and positive LR were respectively of 94%, 67% and 8.75 when analysing for “high” septic risk only. The test helps to avoid hospitalisations in 1/29 patients and to defer antibiotic in 1/7 patients. Follow-up and drug management remained unchanged in 95% and 89% of patients, respectively.</p> Conclusion <p>Synofast® seems to be a valuable tool for the exclusion of SA. The results need to be confirmed in a larger population, especially the impact on management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Use of Synofast® in routine rheumatology practice: diagnostic performance and impact on management of an acute arthritis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月22日

查看全文
  • F. Badaire,
  • C. Lambert,
  • C. Chen Wa,
  • Y. Oyouba,
  • R. Marjorie,
  • F. Aupetit,
  • N. Guérin,
  • Sylvain Mathieu,
  • A. Tournadre,
  • Marion Couderc

摘要

Background

Septic arthritis (SA) is a rare but serious disease. There is no reliable marker for rapid diagnosis. Synofast® is a new device that analyses synovial fluid and can accurately rule out SA within 15 minutes.

Objective

To evaluate the diagnostic performance of Synofast® in routine practice in patients with suspected SA and to assess its impact on patient care.

Method

This was a monocentric prospective study of patients with acute arthritis of possible septic origin. In addition to the usual blood and synovial bacteriological tests, a drop of synovial fluid was taken for the Synofast® test, which provides three SA risk probabilities: “low”, “possible” or “high”. The physician recorded the management he would have given before the test and the management he actually gave after the test, knowing the diagnostic performance reported in previous studies.

Results

Over one year, 43 patients were included, of whom eight had SA (18.6%). Sensitivity, negative predictive value (PV) and negative likelihood ratio (LR) were respectively of 75%, 93% and 0.32 when analysing for “high” and “possible” septic risk while specificity, positive PV and positive LR were respectively of 94%, 67% and 8.75 when analysing for “high” septic risk only. The test helps to avoid hospitalisations in 1/29 patients and to defer antibiotic in 1/7 patients. Follow-up and drug management remained unchanged in 95% and 89% of patients, respectively.

Conclusion

Synofast® seems to be a valuable tool for the exclusion of SA. The results need to be confirmed in a larger population, especially the impact on management.